Antitrust issues may halt Dankner's Hapoalim move

Nochi Dankner is currently in the process of negotiating two separate deals, which would make him Shari Arison's partner in controlling Bank Hapoalim

September 20, 2006 08:51
2 minute read.
bank hapoalim 88 298

bank hapoalim 88 298. (photo credit: Ariel Jerozolimski)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The intention of Nochi Dankner, chairman and controlling shareholder of IDB Holdings Corp. Ltd., to acquire a substantial interest in Bank Hapoalim's controlling core might be squashed by opposition from the Israel Antitrust Authority. "It has come to our attention that Ronit Kan, the director-general of the Antitrust Authority does not like the deal," said Alon Glazer, a banking analyst at Leader & Co. "The concern is that Dankner, who through IDB - Israel's biggest holding company - already controls a large part of Israeli companies, would also be gaining partial control of the country's largest lender." Glazer added though that it looked like the Bank of Israel would be in favor of the deal. Dankner is in the process of negotiating two separate deals, which would make him Shari Arison's partner in controlling Bank Hapoalim. A source familiar with antitrust matters said, however, that there could be a conflict of interest. "If IDB, which controls a large number of companies, would be part of the controlling core of the biggest creditor in the market, this might raise concerns over IDB's influence on blocking credit to competitors and conditions of free competition," said the source. The Antitrust Authority said it had not yet received a formal notification of the transactions. This week, Dankner's IDB Development Corp. said it was in talks to buy control of Israel Salt Industries Ltd., owner of 6 percent of Bank Hapoalim, of which 3% are part of the controlling core. "Dankner may end up having to pay a premium for Salt Industries to persuade the Arison family to give up their controlling interest in Bank Hapoalim," said Glazer. At the same time, Dankner is also in talks to buy up the 5.5% stake owned by foreign shareholders. "The US shareholders are interested in selling their interest, which Dankner should be able to acquire at a lower price around the market value," said Glazer. If the two transactions come through and Dankner obtains regulatory approval, the 20% controlling interest would consist of Arison with 11.5% of Bank Hapoalim, and Nochi Dankner with 8.5%. Arison would own 57.5% of the controlling interest, while IDB Development would own 42.5%. Independent of whether the two transactions go through, Arison will continue to be the leading controlling shareholder of the bank. This week, Arison, chairwoman of the Arison Group, said she was examining the various aspects of Dankner joining the controlling group. Arison has the right of first refusal regarding the other shareholders of the bank. "Arison knows Dankner very well and has worked well with him before, so she is not likely to make use of her right of first refusal," said Glazer.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection